These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 19509180

  • 1. Successes and challenges in translational research: the development of targeted therapy for gastrointestinal stromal tumours.
    Renouf DJ, Wilson L, Blanke CD.
    Clin Cancer Res; 2009 Jun 15; 15(12):3908-11. PubMed ID: 19509180
    [Abstract] [Full Text] [Related]

  • 2. Gastrointestinal stromal tumors and the evolution of targeted therapy.
    Sanborn RE, Blanke CD.
    Clin Adv Hematol Oncol; 2005 Aug 15; 3(8):647-57. PubMed ID: 16167051
    [Abstract] [Full Text] [Related]

  • 3. Gastrointestinal stromal tumors (GISTs): a pathology view point.
    Sornmayura P.
    J Med Assoc Thai; 2009 Jan 15; 92(1):124-35. PubMed ID: 19260254
    [Abstract] [Full Text] [Related]

  • 4. Gastrointestinal stromal tumors.
    von Mehren M, Watson JC.
    Hematol Oncol Clin North Am; 2005 Jun 15; 19(3):547-64, vii. PubMed ID: 15939196
    [Abstract] [Full Text] [Related]

  • 5. Gastrointestinal stromal tumours.
    Connolly EM, Gaffney E, Reynolds JV.
    Br J Surg; 2003 Oct 15; 90(10):1178-86. PubMed ID: 14515284
    [Abstract] [Full Text] [Related]

  • 6. Gastrointestinal stromal tumours: clinical overview, surgery and recent advances in imatinib mesylate therapy.
    Samelis GF, Ekmektzoglou KA, Zografos GC.
    Eur J Surg Oncol; 2007 Oct 15; 33(8):942-50. PubMed ID: 17196360
    [Abstract] [Full Text] [Related]

  • 7. Gastric GISTs. Personal experience.
    Mingolla GP, Riccio PA, Linguerri R, La Donna M, Zannelli M, Artuso S.
    Ann Ital Chir; 2007 Oct 15; 78(4):283-8; discussion 288-9. PubMed ID: 17990602
    [Abstract] [Full Text] [Related]

  • 8. [Imatinib and solid tumours].
    Arifi S, El Sayadi H, Dufresne A, Ray-Coquard I, Fayette J, Méeus P, Ranchère D, Decouvelaere AV, Alberti L, Tabone-Eglinger S, Blay JY, Cassier P.
    Bull Cancer; 2008 Jan 15; 95(1):99-106. PubMed ID: 18230575
    [Abstract] [Full Text] [Related]

  • 9. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors.
    Perez EA, Livingstone AS, Franceschi D, Rocha-Lima C, Lee DJ, Hodgson N, Jorda M, Koniaris LG.
    J Am Coll Surg; 2006 Apr 15; 202(4):623-9. PubMed ID: 16571433
    [Abstract] [Full Text] [Related]

  • 10. [Imatinib mesylate STI571 therapy for five patients with advanced gastrointestinal stromal tumors].
    Shen KT, Hou YY, Qin XY, Song LJ, Sujie A.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Mar 15; 8(2):129-31. PubMed ID: 16155822
    [Abstract] [Full Text] [Related]

  • 11. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E, Merkelbach-Bruse S, Büttner R, Schildhaus HU.
    Verh Dtsch Ges Pathol; 2007 Mar 15; 91():165-8. PubMed ID: 18314611
    [Abstract] [Full Text] [Related]

  • 12. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K, Matsumoto T, Hirota S.
    Gan To Kagaku Ryoho; 2009 Jul 15; 36(7):1080-5. PubMed ID: 19620796
    [Abstract] [Full Text] [Related]

  • 13. Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.
    Heinrich MC, Corless CL.
    J Surg Oncol; 2005 Jun 01; 90(3):195-207; discussion 207. PubMed ID: 15895440
    [Abstract] [Full Text] [Related]

  • 14. Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
    Griffin JM, Amand MS, Demetri GD.
    Clin J Oncol Nurs; 2005 Apr 01; 9(2):161-9. PubMed ID: 15853160
    [Abstract] [Full Text] [Related]

  • 15. [Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor].
    Gelderblom H, Hogendoorn PC, van der Graaf WT, Verweij J.
    Ned Tijdschr Geneeskd; 2003 Oct 18; 147(42):2051-5. PubMed ID: 14606351
    [Abstract] [Full Text] [Related]

  • 16. Imatinib mesilate for the treatment of gastrointestinal stromal tumour.
    Cassier PA, Dufresne A, Arifi S, El Sayadi H, Labidi I, Ray-Coquard I, Tabone S, Méeus P, Ranchère D, Sunyach MP, Decouvelaere AV, Alberti L, Blay JY.
    Expert Opin Pharmacother; 2008 May 18; 9(7):1211-22. PubMed ID: 18422477
    [Abstract] [Full Text] [Related]

  • 17. A pilot study of imatinib mesylate (STI571) on gastrointestinal stromal tumors in Japanese patients.
    Sawaki A, Yamao K, Nakamura T, Suzuki T, Okubo K, Hara K, Kawai H, Yamamura Y, Ito S, Mochiduki Y, Ohno R.
    J Gastroenterol; 2004 May 18; 39(4):329-33. PubMed ID: 15168243
    [Abstract] [Full Text] [Related]

  • 18. Could imatinib replace surgery in esophageal gastrointestinal stromal tumor.
    Al-Salam S, El-Teraifi HA, Taha MS.
    Saudi Med J; 2006 Aug 18; 27(8):1236-9. PubMed ID: 16883460
    [Abstract] [Full Text] [Related]

  • 19. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment.
    Benjamin RS, Debiec-Rychter M, Le Cesne A, Sleijfer S, Demetri GD, Joensuu H, Schöffski P, Poveda A.
    Semin Oncol; 2009 Aug 18; 36(4):302-11. PubMed ID: 19664491
    [Abstract] [Full Text] [Related]

  • 20. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B, Hornick JL, Antonescu CR, Corless CL, Fletcher CD.
    Am J Surg Pathol; 2009 Feb 18; 33(2):218-26. PubMed ID: 18830121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.